Nonthyroidal illness syndrome

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 20, Issue 5, 2013, Pages 478-484

  Farwell, Alan P ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

illness; nonthyroidal; syndrome

Indexed keywords

BINDING PROTEIN; LIOTHYRONINE; THYROID HORMONE; THYROID HORMONE RECEPTOR; THYROTROPIN; THYROXINE;

BRAIN DEATH; CARDIOPULMONARY BYPASS; CORONARY ARTERY BYPASS SURGERY; ENDOCRINE DISEASE; ENZYME ACTIVITY; EUTHYROID SICK SYNDROME; HEART MUSCLE CONTRACTILITY; HEART SURGERY; HORMONE RELEASE; HUMAN; HYPOTHALAMUS; NONTHYROIDAL ILLNESS SYNDROME; ORGAN DONOR; PREMATURITY; REVIEW; STARVATION; THYROID FUNCTION; THYROID HORMONE METABOLISM;

ACUTE DISEASE; ANIMALS; CHRONIC DISEASE; EUTHYROID SICK SYNDROMES; HEART; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE, DISEASES; THORACIC SURGERY; THYROID HORMONES;

EID: 84883657666     PISSN: 1752296X     EISSN: 17522978     Source Type: Journal    
DOI: 10.1097/01.med.0000433069.09294.e8     Document Type: Review

References (58)

1. Haddady S, Farwell AP. Non-thyroidal illness and the management of thyroid disorders in the Intensive Care Unit. In: Irwin RS, Rippe JM, editors. Intensive care medicine. Philadelphia: Lippincott Williams & Wilkins; 2011.
2. Farwell A. Thyroid hormone therapy is not indicated in the majority of patients with the sick euthyroid syndrome. Endocr Pract 2008; 14:1180-1187.
3. Warner MH, Beckett GJ. Mechanisms behind the non-thyroidal illness syndrome: an update. J Endocrinol 2010; 205:1-13.
4. Boelen A, Kwakkel J, Fliers E. Beyond low plasma T3: local thyroid hormone metabolism during inflammation and infection. Endocr Rev 2011; 32:670-693.
5. Pappa TA, Vagenakis AG, Alevizaki M. The nonthyroidal illness syndrome in the non-critically ill patient. Eur J Clin Invest 2011; 41:212-220.
6. Kaptein EM, Sanchez A, Beale E, et al. Clinical review: thyroid hormone therapy for postoperative nonthyroidal illnesses - a systematic review and synthesis. J Clin Endocrinol Metab 2010; 95:4526-4534.
7. Bianco AC, Kim BW. Intracellular pathways of oodothyronine metabolism/implications of deiodinations for thyroid hormone action. In: Braverman LE, Cooper DS, editors. Werner and Ingbar's The Thyroid. Philadelphia: Lippincott-Williams and Wilkins; 2013. pp. 103-126.
8. Huang SA, Bianco AC. Reawakened interest in type III iodothyronine deiodinase in critical illness and injury. Nat Clin Pract Endocrinol Metab 2008; 4:148-155. (Pubitemid 351301780)
9. Mebis L, Langouche L, Visser TJ, et al. The type II iodothyronine deiodinase is up-regulated in skeletal muscle during prolonged critical illness. J Clin Endocrinol Metab 2007; 92:3330-3333. (Pubitemid 47236410)
10. Peeters RP, van der Geyten S, Wouters PJ, et al. Tissue thyroid hormone levels in critical illness. J Clin Endocrinol Metab 2005; 90:6498-6507. (Pubitemid 41759305)
11. Coppola A, Liu ZW, Andrews ZB, et al. A central thermogenic-like mechanism in feeding regulation: an interplay between arcuate nucleus T3 and UCP2. Cell Metab 2007; 5:21-33. (Pubitemid 44939398)
12. Fekete C, Gereben B, Doleschall M, et al. Lipopolysaccharide induces type 2 iodothyronine deiodinase in the mediobasal hypothalamus: implications for the nonthyroidal illness syndrome. Endocrinology 2004; 145:1649-1655. (Pubitemid 38402371)
13. Maia AL, Kim BW, Huang SA, et al. Type 2 iodothyronine deiodinase is the major source of plasma T3 in euthyroid humans. J Clin Invest 2005; 115: 2524-2533. (Pubitemid 41266215)
14. Larsen PR. Type 2 iodothyronine deiodinase in human skeletal muscle: new insights into its physiological role and regulation. J Clin Endocrinol Metab 2009; 94:1893-1895.
15. Heemstra KA, Soeters MR, Fliers E, et al. Type 2 iodothyronine deiodinase in skeletal muscle: effects of hypothyroidism and fasting. J Clin Endocrinol Metab 2009; 94:2144-2150.
16. Galton VA, Schneider MJ, Clark AS, et al. Life without thyroxine to 3,5,3'- triiodothyronine conversion: studies in mice devoid of the 5'-deiodinases. Endocrinology 2009; 150:2957-2963.
17. St Germain DL, Galton VA, Hernandez A. Minireview: defining the roles of the iodothyronine deiodinases - current concepts and challenges. Endocrinology 2009; 150:1097-1107.
18. van den Berghe G, de Zegher F, Lauwers P. Dopamine and the sick euthyroid syndrome in critical illness. Clin Endocrinol 1994; 41:731-737.
19. Hsieh CJ, Wang PW, Wang ST, et al. Serum leptin concentrations of patients with sequential thyroid function changes. Clin Endocrinol (Oxf) 2002; 57:29-34.
20. Corsonello A, Buemi M, Artemisia A, et al. Plasma leptin concentrations in relation to sick euthyroid syndrome in elderly patients with nonthyroidal illnesses. Gerontology 2000; 46:64-70. (Pubitemid 30103516)
21. van den Berghe G, Wouters P, Weekers F, et al. Reactivation of pituitary hormone release and metabolic improvement by infusion of growth hormonereleasing peptide and thyrotropin-releasing hormone in patients with protracted critical illness. J Clin Endocrinol Metab 1999; 84:1311-1323. (Pubitemid 30644393)
22. Benvenga S. Thyroid hormone transport proteins and the physiology of hormone binding. In: Braverman LE, Cooper DS, editors. Werner and Ingbar's The Thyroid. Philadelphia: Lippincott-Williams & Wilkins; 2013. pp. 97-108.
23. Afandi B, SchusslerGC, Arafeh AH, et al. Selective consumption of thyroxinebinding globulin during cardiac bypass surgery. Metabolism 2000; 49:270-274. (Pubitemid 30090896)
24. Lim CF, Docter R, Visser TJ, et al. Inhibition of thyroxine transport into cultured rat hepatocytes by serum of nonuremic critically ill patients: effects of bilirubin and non-esterified fatty acids. J Clin Endocrinol Metab 1993; 76:1165-1172. (Pubitemid 23155430)
25. Stockigt JR, Lim CF. Medications that distort in vitro tests of thyroid function, with particular reference to estimates of serum free thyroxine. Best Pract Res Clin Endocrinol Metab 2009; 23:753-767.
26. Visser WE, Friesema EC, Visser TJ. Minireview: thyroid hormone transporters - the knowns and the unknowns. Mol Endocrinol 2011; 25:1-14.
27. Sugiyama D, Kusuhara H, Taniguchi H, et al. Functional characterization of rat brain-specific organic anion transporter (Oatp14) at the blood-brain barrier: high affinity transporter for thyroxine. J Biol Chem 2003; 278:43489-43495. (Pubitemid 37345972)
28. Heuer H, Maier MK, Iden S, et al. The monocarboxylate transporter 8 linked to human psychomotor retardation is highly expressed in thyroid hormonesensitive neuron populations. Endocrinology 2005; 146:1701-1706. (Pubitemid 40396877)
29. Hennemann G, Krenning EP. The kinetics of thyroid hormone transporters and their role in non-thyroidal illness and starvation. Best Pract Res Clin Endocrinol Metab 2007; 21:323-338. (Pubitemid 46888198)
30. Mebis L, Debaveye Y, Ellger B, et al. Changes in the central component of the hypothalamus-pituitary-thyroid axis in a rabbit model of prolonged critical illness. Crit Care 2009; 13:R147.
31. Oetting A, Yen PM. New insights into thyroid hormone action. Best Pract Res Clin Endocrinol Metab 2007; 21:193-208. (Pubitemid 46888201)
32. Feingold K, Kim MS, Shigenaga J, et al. Altered expression of nuclear hormone receptors and coactivators in mouse heart during the acute-phase response. Am J Physiol Endocrinol Metab 2004; 286:E201-E207. (Pubitemid 38140310)
33. Williams GR, Franklyn JA, Neuberger JM, et al. Thyroid hormone receptor expression in the 'sick euthyroid' syndrome. Lancet 1989; 2:1477-1481. (Pubitemid 20018141)
34. Pingitore A, Landi P, Taddei MC, et al. Triiodothyronine levels for risk stratification of patients with chronic heart failure. Am J Med 2005; 118: 132-136. (Pubitemid 40202859)
35. Frey A, Kroiss M, Berliner D, et al. Prognostic impact of subclinical thyroid dysfunction in heart failure. Int J Cardiol 2012; [Epub ahead of print]. doi: 10.1016/j.ijcard.2012.09.064.
36. Horacek J, Dusilova Sulkova S, Kubisova M, et al. Thyroid hormone abnormalities in hemodialyzed patients: low triiodothyronine as well as high reverse triiodothyronine are associated with increased mortality. Physiol Res 2012; 61:495-501.
37. Wang F, Pan W, Wang H, et al. Relationship between thyroid function and ICU mortality: a prospective observation study. Crit Care 2012; 16:R11.
38. DeGroot LJ. 'Non-thyroidal illness syndrome' is functional central hypothyroidism, and if severe, hormone replacement is appropriate in light of present knowledge. J Endocrinol Invest 2003; 26:1163-1170.
39. Peeters RP, Wouters PJ, van Toor H, et al. Serum 3,3',5'-triiodothyronine (rT3) and 3,5,3'-triiodothyronine/rT3 are prognostic markers in critically ill patients and are associated with postmortem tissue deiodinase activities. J Clin Endocrinol Metab 2005; 90:4559-4565. (Pubitemid 41159343)
40. Kaptein EM, Beale E, Chan LS. Thyroid hormone therapy for obesity and nonthyroidal illnesses: a systematic review. J Clin Endocrinol Metab 2009; 94:3663-3675.
41. Langouche L, Vander Perre S, Marques M, et al. Impact of early nutrient restriction during critical illness on the nonthyroidal illness syndrome and its relation with outcome: a randomized, controlled clinical study. J Clin Endocrinol Metab 2013; 98:1006-1013.
42. Plikat K, Langgartner J, Buettner R, et al. Frequency and outcome of patients with nonthyroidal illness syndrome in a medical intensive care unit. Metabolism 2007; 56:239-244. (Pubitemid 46074071)
43. Obregon MJ, Calvo RM, Del Rey FE, et al. Ontogenesis of thyroid function and interactions with maternal function. Endocr Dev 2007; 10:86-98.
44. Bernal J. Thyroid hormones and brain development. Vitam Horm 2005; 71:95-122. (Pubitemid 43589035)
45. Rovet J, Daneman D. Congenital hypothyroidism: a review of current diagnostic and treatment practices in relation to neuropsychologic outcome. Paediatr Drugs 2003; 5:141-149. (Pubitemid 36363548)
46. Osborn DA. Thyroid hormones for preventing neurodevelopmental impairment in preterm infants. Cochrane Database Syst Rev 2001; CD001070.
47. Novitzky D, Cooper DK, Rosendale JD, et al. Hormonal therapy of the braindead organ donor: experimental and clinical studies. Transplantation 2006; 82:1396-1401. (Pubitemid 44967616)
48. Goarin J-P, Cohen S, Riou B, et al. The effects of triiodothyronine on hemodynamic status and cardiac function in potential heart donors. Anest Anal 1996; 83:41-47. (Pubitemid 26225372)
49. Jeevanandam V. Triiodothyronine: spectrum of use in heart transplantation. Thyroid 1997; 7:139-145. (Pubitemid 27132908)
50. Zaroff JG, Rosengard BR, Armstrong WF, et al. Consensus conference report: maximizing use of organs recovered from the cadaver donor: cardiac recommendations, March 28-29, 2001, Crystal City, Va. Circulation 2002; 106:836-841.
51. Cooper DK, Novitzky D, Wicomb WN, et al. A review of studies relating to thyroid hormone therapy in brain-dead organ donors. Front Biosci 2009; 14:3750-3770.
52. Dikdan GS, Mora-Esteves C, Koneru B. Review of randomized clinical trials of donor management and organ preservation in deceased donors: opportunities and issues. Transplantation 2012; 94:425-441.
53. Ladenson PW. Thyroid hormone analogues: ready for prime time. Thyroid 2011; 21:101-102.
54. D'Aloia A, Vizzardi E, Bugatti S, et al. Effect of short-term infusive dobutamine therapy on thyroid hormone profile and hemodynamic parameters in patients with acute worsening heart failure and low-triiodothyronine syndrome. J Investig Med 2012; 60:907-910.
55. Iervasi G, Pingitore A, Landi P, et al. Low-T3 syndrome: a strong prognostic predictor of death in patients with heart disease. Circulation 2003; 107:708-713. (Pubitemid 36222598)
56. Moruzzi P, Doria E, Agostoni PG. Medium-term effectiveness of L-thyroxine treatment in idiopathic dilated cardiomyopathy. Am J Med 1996; 101:461-467. (Pubitemid 126335965)
57. Hamilton MA, Stevenson LW, Fonarow GC, et al. Safety and hemodynamic effects of intravenous triiodothyronine in advanced congestive heart failure. Am J Cardiol 1998; 81:443-447. (Pubitemid 28099535)
58. Pingitore A, Galli E, Barison A, et al. Acute effects of triiodothyronine (t3) replacement therapy in patients with chronic heart failure and low-t3 syndrome: a randomized, placebo-controlled study. J Clin Endocrinol Metab 2008; 93:1351-1358. (Pubitemid 351519732)